This announcement is for informational purposes only and is not an offer to sell orthe solicitation of an offer to buy securities in the United States or in anyother jurisdiction in which such offer, solicitation or sale would be unlawfulprior to registration or qualification under the securities laws of any suchjurisdiction. Neither this announcement nor anything herein forms the basis forany contract or commitment whatsoever. Neither this announcement nor any copy here of may be taken into or distributed in the United States. The securitiesreferred to herein have not been and will not be registered under the UnitedStates Securities Act of 1933, as amended, and may not be offered or sold inthe United States absent registration or an applicable exemption fromregistration. Any public offering of securities to be made in the United Stateswill be made by means of a prospectus. Such prospectus will contain detailed information about the Company and management, as well as financial statements.No public offer of securities is to be made by the Company in the UnitedStates.

This pressrelease contains forward-looking statements and you are cautioned not to placeundue reliance on any forward-looking statements contained herein. We can giveno assurance that these forward-looking statements will prove to have beencorrect. Expectations reflected in these forward-looking statements are subjectto change and we undertake no obligation and do not intend to update or reviseany forward-looking statements herein.

Charmacy Pharmaceutical SuccessfullyListed on the Main Board of

The Stock Exchange of Hong Kong

Total turnover of approximately HK$ 64.44 million

[14 December 2015, Hong Kong] Charmacy Pharmaceutical Co., Ltd. (“Charmacy Pharmaceutical” or the “Company”; stock code: 2289.HK), one of the leading pharmaceuticaldistributors in Southern China, began trading on the Main Board of TheStock Exchange of Hong Kong Limited (“HKEX”) today.

A total of approximately 8.02 million shares were changed hands, with an aggregate turnoverof approximately HK$ 64.44 million.

Mr. Yao Chuanglong, Chairman,Executive Director and CEO of Charmacy Pharmaceutical, said, “Thesuccessful listing on the HKExsignifies the beginning of a new stage in the international capitalmarket, and it marks an important milestone of the Company as well. We arehonored to receive enthusiastic support from our investors. Standing at a newstarting point, we will continue expanding our business scale. Weplan to establish our new distribution center through acquiringmature pharmaceutical distribution business in the Southern China region, so as to enlarge ourcustomer base and deepen our market penetration. Meanwhile, Charmacy Pharmaceutical will further develop our B2B e-commerce platform anddiversify our product mix, thereby creating fruitful value for shareholders. We are confident in the long term development of the Company.”

Mr. Yao Chuanglong, Chairman,Executive Director and CEO of Charmacy Pharmaceutical, (6th from left),together with other guests.

Mr. Yao Chuanglong, Chairman, Executive Director and CEO of Charmacy Pharmaceutical, said,” The successful listing on the HKExsignifies the beginning of a new stage in the international capitalmarket, and it marks an important milestone of the Company as well.”

About Charmacy Pharmaceutical Co., Ltd.

Charmacy Pharmaceutical Co.,Ltd. (stock code: 2289.HK) is one of the leading pharmaceutical distributors inSouthern China; its distribution network includes Southern China and otherregions, such as Fujian Province and it distributes the products to distributorcustomers, retail pharmacy stores, and hospitals, clinics, health centers andothers. Charmacy Pharmaceutical is the third largest privately-owned pharmaceutical distribution company in the Southern China in terms of revenuegenerated from pharmaceutical distribution business in 2014. Charmacy Pharmaceutical has a variety of product offerings including western medicines,Chinese patent medicines, healthcare products, Chinese medicine material anddecoction pieces, medical devices and cosmetic products. In June 2015, Charmacy Pharmaceutical started the pilot run of its B2B e-commerce platform and itexpects the platform will operate in full scale in the fourth quarter of 2015in order to offer a more convenient service to clients. Charmacy Pharmaceutical plans to strengthen, expand and integrate its existingdistribution network and capabilities to increase distribution coverage,capacity and operating efficiencies and lower our cost and plan to upgrade andpromote its B2B e-commerce platform to enhance its market position in SouthernChina.

Issued by Porda HavasInternational Finance Communications Group for and on behalf of Charmacy Pharmaceutical Co., Ltd. For further information, please contact:

Fax: +852 3150 6728